Summary & Overview
HCPCS J7203: Injection Factor IX, Recombinant Glycopegylated (Rebinyn), 1 IU
HCPCS Level II code J7203 designates recombinant factor IX, glycopegylated (Rebinyn), dosed per international unit for replacement therapy in hemophilia B. This injectable biologic is integral to managing bleeding episodes and prophylaxis for patients with factor IX deficiency. Nationally, biologic factor therapies represent a high-cost, high-clinical-impact segment of specialty pharmacy and infusion services, with implications for site-of-care decisions and utilization management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical role of J7203, typical sites of service where the product is administered, and the payer landscape relevant to reimbursement and coverage policy. The publication summarizes benchmarks related to utilization and billing practice, highlights policy and coverage considerations that commonly affect access and prior authorization, and situates J7203 within broader specialty drug management strategies. Clinical context about hemophilia B and the therapeutic purpose of factor IX replacement is provided to inform payer and provider stakeholders about appropriate coding and service delivery considerations.
Data not available in the input: specific ICD-10 mappings, taxonomies, related codes, detailed payer-specific coverage rules, and service-line financial benchmarks.
Billing Code Overview
HCPCS Level II code J7203 describes injection factor IX, (antihemophilic factor, recombinant), glycopegylated, (Rebinyn), 1 IU. This code represents a recombinant factor IX concentrate used for replacement therapy in patients with hemophilia B to prevent or control bleeding.
-
Service type: Injectable biologic replacement therapy
-
Typical site of service: Ambulatory infusion centers, hospital outpatient departments, and physician offices where intravenous or subcutaneous biologic infusions are administered
Clinical & Coding Specifications
Clinical Context
A male patient with moderate to severe hemophilia B presents to an outpatient infusion center for routine prophylactic replacement therapy with recombinant, glycopegylated factor IX (J7203). The patient has a history of recurrent joint bleeding and requires scheduled intravenous infusion every 7 to 14 days per hematology plan of care. On arrival, nursing verifies identity, weight, current factor trough/history, and recent inhibitor screens. Peripheral IV access is obtained; vital signs and site allergy review are documented. The prescribed vial-based IU dose is calculated from the patient’s weight and the ordered international units, and pharmacy prepares the syringe or infusion bag using aseptic technique. The infusion nurse administers J7203 intravenously per institutional infusion rate guidelines, monitors for hypersensitivity or infusion reactions, documents lot and vial numbers, and records administered IU and time. Post-infusion assessment confirms hemostatic response and provides home care education; subsequent dose scheduling is coordinated with the hematology team.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; placeholder when no other modifier applies and payer requires two-character entry |